The FDA allows the abortion drug mifepristone to be administered to chemically abort a child up to 10 weeks into a mother’s pregnancy.
The lawsuit also challenged the FDA’s deregulation of the drug, which allowed it to be prescribed without an in-person doctor’s visit and to be dispensed through the mail.
“The sadness of a woman just being alone, unaccompanied — I don’t think people are aware of the harmful effects. It’s because we love women that we’re concerned that this pill remains so accessible,” Burbidge said from the Omni Louisville Hotel, where the USCCB’s spring meeting is being held.
A study published by the U.S. bishops cites safety concerns with the abortion pill, including blood loss, infections, and even death. The study notes that the rate of adverse effects from chemical abortions is more than 5%, which is four times higher than with first-trimester surgical abortions.
The bishops will continue to focus their efforts on helping women in need and educating people about the safety concerns of the abortion pill, he said, adding that women would not choose to have an abortion if they had the support they need.
“We’re going to surround them, hopefully, accompany them, love them, provide for them in every way possible,” he said, adding that the bishops’ Walking with Moms in Need program has expanded options for pregnant women facing difficult situations.
Credit: Source link
